Teva

Teva strides ahead in Q2

Teva strides ahead in Q2

By Anna Lewcock

Generics giant Teva has announced results for the second quarter of
the financial year showing record-breaking sales, thanks to an
impressive performance from MS drug Copaxone (glatiramer acetate)
and the early launch of generic Lotrel...

Teva closer to SICOR merger

Teva closer to SICOR merger

Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers